Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

A live webcast of the fireside chat can be accessed under ... Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health, GSK, said: “At ViiV Healthcare we believe that everyone, no matter where they live, should have the freedom to be their authentic ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

We will deliver our fully reinvigorated portfolio to market efficiently and maximise the considerable commercial potential, ...